Cefpodoxime proxetil: a new, broad-spectrum, oral cephalosporin
- PMID: 8286813
- DOI: 10.1177/106002809302701111
Cefpodoxime proxetil: a new, broad-spectrum, oral cephalosporin
Abstract
Objective: To discuss the chemistry, pharmacokinetics, spectrum of activity, clinical trials, adverse effects, drug interactions, and dosage guidelines of cefpodoxime proxetil.
Data sources: Literature was identified through a MEDLINE search from 1988 to the present and from review of bibliographies in that literature.
Study selection: Data were limited to comparative trials published in the English literature. Although many studies were conducted in Japan, the results often were available only in Japanese or partly in English. As these studies could not be completely evaluated, they are not included in this review.
Data synthesis: Cefpodoxime exhibits good activity against many gram-positive and gram-negative organisms. In clinical trials, cefpodoxime was similar in both clinical and bacteriologic efficacy to amoxicillin, cefaclor, amoxicillin/clavulanate, and penicillin in the treatment of respiratory and urinary tract infections. It also appeared effective in the treatment of skin and soft tissue infections, although no comparative trials have been performed. Cefpodoxime is well tolerated by children and is effective in the treatment of otitis media and pharyngitis. It has a similar adverse effect profile to that of other penicillins and cephalosporins, with gastrointestinal effects being most common.
Conclusions: Cefpodoxime demonstrates good in vitro activity against pathogens frequently associated with respiratory tract, urinary tract, and skin and tissue infections. It has not demonstrated greater efficacy than the other antibiotics to which it has been compared. The available published clinical trials are fraught with methodologic, statistical, and evaluative flaws. Thus, further trials comparing cefpodoxime with established treatments, as well as the newer cephalosporins, are needed before its place in therapy can be established.
Similar articles
-
Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients.Paediatr Drugs. 2001;3(2):137-58. doi: 10.2165/00128072-200103020-00006. Paediatr Drugs. 2001. PMID: 11269640 Review.
-
Cefpodoxime proxetil. An appraisal of its use in antibacterial cost-containment programmes, as stepdown and abbreviated therapy in respiratory tract infections.Pharmacoeconomics. 1996 Aug;10(2):164-78. doi: 10.2165/00019053-199610020-00008. Pharmacoeconomics. 1996. PMID: 10163419 Review.
-
Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten.Ann Pharmacother. 1996 Mar;30(3):258-68. doi: 10.1177/106002809603000310. Ann Pharmacother. 1996. PMID: 8833562 Review.
-
[Clinical evaluation of a new oral cephem, cefpodoxime proxetil in children].Jpn J Antibiot. 1989 Jul;42(7):1561-70. Jpn J Antibiot. 1989. PMID: 2810730 Japanese.
-
Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.Drugs. 1992 Nov;44(5):889-917. doi: 10.2165/00003495-199244050-00011. Drugs. 1992. PMID: 1280571 Review.
Cited by
-
FDA-Approved Oximes and Their Significance in Medicinal Chemistry.Pharmaceuticals (Basel). 2022 Jan 4;15(1):66. doi: 10.3390/ph15010066. Pharmaceuticals (Basel). 2022. PMID: 35056123 Free PMC article. Review.
-
Activity of once-daily cefpodoxime regimens against Haemophilus influenzae and Streptococcus pneumoniae with an in vitro pharmacodynamic chamber model.Antimicrob Agents Chemother. 1996 Jun;40(6):1545-7. doi: 10.1128/AAC.40.6.1545. Antimicrob Agents Chemother. 1996. PMID: 8726036 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials